Table 1.
Baseline Characteristics of Women in the Control and the Treatment Group Undergoing Vehicle and Kisspeptin-10 Infusion
| Control Group | Treatment (NK3Ra) Group | P Value | |||
|---|---|---|---|---|---|
| n | 10 | 10 | |||
| Age (y) | 35 ± 5.8 | 35 ± 5.4 | ns | ||
| BMI (kg/m2) | 25 ± 4.6 | 28 ± 6.9 | ns | ||
| Cycle length (d) | 29 ± 1.8 | 28 ± 1.4 | ns | ||
| Vehicle Cycle | Kp-10 Cycle | P Value | Vehicle Cycle | Kp-10 Cycle | P Value | |
|---|---|---|---|---|---|---|
| Menstrual cycle day | 9.2 ± 0.8 | 9.4 ± 0.8 | ns | 4.4 ± 0.5 | 4.8 ± 0.8 | ns |
| LH (IU/L) | 4.8 ± 2.1 | 5.6 ± 2.0 | ns | 5.0 ± 1.8 | 4.9 ± 1.8 | ns |
| FSH (IU/L) | 4.3 ± 1.2 | 5.3 ± 2.6 | ns | 6.2 ± 1.8 | 5.5 ± 1.3 | ns |
| Estradiol (pmol/L) | 274 ± 126 | 287 ± 157 | ns | 121 ± 54 | 154 ± 47 | ns |
Data are shown as mean + SD; BMI, Body Mass Index; Kp-10, Kisspeptin-10; ns, not significant. Note that baseline data on control and treatment groups in lower part of the table reflect sampling at different stages of the menstrual cycle.